GT Biopharma Inc
GTBP0.845USD
+0.040+4.97%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
5.11MMarket Cap
LossP/E TTM
More Details of GT Biopharma Inc Company
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
GT Biopharma Inc Info
Ticker SymbolGTBP
Company nameGT Biopharma Inc
IPO dateOct 22, 2013
CEOBreen (Michael)
Number of employees1
Security typeOrdinary Share
Fiscal year-endOct 22
Address505 Montgomery Street
CitySAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94111
Phone18003049888
Websitehttps://www.gtbiopharma.com/
Ticker SymbolGTBP
IPO dateOct 22, 2013
CEOBreen (Michael)
Company Executives of GT Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Hilary Kramer
Ms. Hilary Kramer
Independent Director
Independent Director
--
--
Mr. Corey Davis
Mr. Corey Davis
IR Contact Officer
IR Contact Officer
--
--
Mr. David Mun-Gavin
Mr. David Mun-Gavin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Alan Louis Urban
Mr. Alan Louis Urban
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
--
--
Mr. Michael Breen
Mr. Michael Breen
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Hilary Kramer
Ms. Hilary Kramer
Independent Director
Independent Director
--
--
Mr. Corey Davis
Mr. Corey Davis
IR Contact Officer
IR Contact Officer
--
--
Mr. David Mun-Gavin
Mr. David Mun-Gavin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Alan Louis Urban
Mr. Alan Louis Urban
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
--
--
Mr. Michael Breen
Mr. Michael Breen
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bristol Capital Advisors, LLC
2.11%
Five Narrow Lane LP
2.11%
Cytovance Biologics Inc
2.06%
Marzilli (Robert A)
1.88%
DRW Securities, LLC
1.34%
Other
90.50%
Shareholders
Shareholders
Proportion
Bristol Capital Advisors, LLC
2.11%
Five Narrow Lane LP
2.11%
Cytovance Biologics Inc
2.06%
Marzilli (Robert A)
1.88%
DRW Securities, LLC
1.34%
Other
90.50%
Shareholder Types
Shareholders
Proportion
Corporation
4.17%
Hedge Fund
3.74%
Investment Advisor
2.82%
Individual Investor
2.68%
Investment Advisor/Hedge Fund
0.23%
Research Firm
0.10%
Other
86.26%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
59
539.33K
15.18%
-858.08K
2025Q2
66
1.25M
38.22%
-642.80K
2025Q1
68
804.53K
32.52%
-1.10M
2024Q4
67
1.69M
77.15%
+250.78K
2024Q3
72
1.78M
83.42%
+447.50K
2024Q2
86
1.49M
74.57%
+1.15M
2024Q1
114
291.84K
21.12%
+12.53K
2023Q4
122
330.03K
23.89%
+44.31K
2023Q3
135
280.81K
22.00%
-118.49K
2023Q2
146
270.35K
22.09%
-126.02K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bristol Capital Advisors, LLC
224.52K
6.31%
+224.52K
--
May 30, 2025
Five Narrow Lane LP
224.40K
6.31%
+224.40K
--
May 30, 2025
Cytovance Biologics Inc
219.46K
6.17%
--
--
May 30, 2025
Marzilli (Robert A)
200.00K
5.62%
--
--
May 30, 2025
Armistice Capital LLC
114.48K
3.22%
+41.97K
+57.89%
May 30, 2025
BMO Nesbitt Burns Inc.
92.53K
2.6%
+77.88K
+531.56%
Jun 30, 2025
Breen (Michael Martin)
45.21K
1.27%
+16.67K
+58.40%
May 30, 2025
BlackRock Institutional Trust Company, N.A.
9.74K
0.3%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 01, 2024
Merger
30→1
Feb 01, 2024
Merger
30→1
Feb 01, 2024
Merger
30→1
Feb 01, 2024
Merger
30→1
Date
Type
Ratio
Feb 01, 2024
Merger
30→1
Feb 01, 2024
Merger
30→1
Feb 01, 2024
Merger
30→1
Feb 01, 2024
Merger
30→1
FAQs
Who are the top five shareholders of GT Biopharma Inc?
The top five shareholders of GT Biopharma Inc are:
Bristol Capital Advisors, LLC holds 224.52K shares, accounting for 6.31% of the total shares.
Five Narrow Lane LP holds 224.40K shares, accounting for 6.31% of the total shares.
Cytovance Biologics Inc holds 219.46K shares, accounting for 6.17% of the total shares.
Marzilli (Robert A) holds 200.00K shares, accounting for 5.62% of the total shares.
Armistice Capital LLC holds 114.48K shares, accounting for 3.22% of the total shares.
Bristol Capital Advisors, LLC holds 224.52K shares, accounting for 6.31% of the total shares.
Five Narrow Lane LP holds 224.40K shares, accounting for 6.31% of the total shares.
Cytovance Biologics Inc holds 219.46K shares, accounting for 6.17% of the total shares.
Marzilli (Robert A) holds 200.00K shares, accounting for 5.62% of the total shares.
Armistice Capital LLC holds 114.48K shares, accounting for 3.22% of the total shares.
What are the top three shareholder types of GT Biopharma Inc?
The top three shareholder types of GT Biopharma Inc are:
Bristol Capital Advisors, LLC
Five Narrow Lane LP
Cytovance Biologics Inc
Bristol Capital Advisors, LLC
Five Narrow Lane LP
Cytovance Biologics Inc
How many institutions hold shares of GT Biopharma Inc (GTBP)?
As of 2025Q3, 59 institutions hold shares of GT Biopharma Inc, with a combined market value of approximately 539.33K, accounting for 15.18% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -23.04%.
What is the biggest source of revenue for GT Biopharma Inc?
In --, the -- business generated the highest revenue for GT Biopharma Inc, amounting to -- and accounting for --% of total revenue.
